PAR 3.92% 24.5¢ paradigm biopharmaceuticals limited..

research reports and media, page-3837

  1. 583 Posts.
    lightbulb Created with Sketch. 245
    Dilution my friends dilution. Yes, $6,000 per course is mathematically better, but please run some numbers. The below has been written up on here before to show the risk / reward of waiting to maximise.
    Also, remember the Chairperson has stated there are no more "large upfronts", those days are over. So if your strategy is to wait and forgo say $100m upfront now for say $500m later (post DMOAD status) you will have to raise capital to keep things going. Play with your own assumptions, but please consider the below.

    1mill p.a. courses sold at $4,500 = $4.5bn revenue (25% royalty) = $1.125bn divided by 283m shares = $3.98c per share in earnings

    1mill courses sold at $6,000 = $6bn (25% royalty) = $1.5bn divided by 383m shares = $3.92 per share
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.